Agents for use in the treatment of retinal inflammation

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 10519232
SERIAL NO

15111986

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SORBONNE UNIVERSITE21 RUE DE L'ÉCOLE DE MÉDECINE PARIS 75006

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Guillonneau, Xavier Boulogne Billancourt, FR 5 2
Levy, Olivier Paris, FR 7 24
Sahel, José-Alain Paris, FR 31 15
Sennlaub, Florian Paris, FR 16 26

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 30, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 30, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00